Cellular and molecular targeting for nanotherapeutics in transplantation tolerance

Kelan A. Hlavaty, Xunrong Luo, Lonnie D. Shea*, Stephen D. Miller

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations


The induction of donor-specific tolerance to transplanted cells and organs, while preserving immune function as a whole, remains a highly sought after and elusive strategy for overcoming transplant rejection. Tolerance necessitates modulating a diverse array of cell types that recognize and respond to alloantigens, including antigen presenting cells and T lymphocytes. Nanotherapeutic strategies that employ cellular and biomaterial engineering represent an emerging technology geared towards the goal of inducing transplant tolerance. Nanocarriers offer a platform for delivering antigens of interest to specific cell types in order to achieve tolerogenic antigen presentation. Furthermore, the technologies also provide an opportunity for local immunomodulation at the graft site. Nanocarriers delivering a combination of antigens and immunomodulating agents, such as rapamycin, provide a unique technology platform with the potential to enhance outcomes for the induction of transplant tolerance.

Original languageEnglish (US)
Pages (from-to)14-23
Number of pages10
JournalClinical Immunology
Issue number1
StatePublished - Sep 1 2015


  • Nanocarrier
  • Targeting
  • Tolerance
  • Transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Cellular and molecular targeting for nanotherapeutics in transplantation tolerance'. Together they form a unique fingerprint.

Cite this